INBP INTEGRATED BIOPHARMA INC
Pharmaceutical Preparations · OTC · SEC CIK 1016504 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-23.1%
TTM net income YoY-644.0%
TTM EPS YoY-650.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin-0.8%
Operating margin-9.3%
Net margin-8.9%
FCF margin-3.8%
EBITDA margin-8.6%
Returns
ROE-19.5%
ROA-14.8%
ROIC (approx.)-20.4%
Asset turnover1.66x
Leverage & solvency
Liabilities / assets29.2%
Debt / equity0.00x
Current ratio2.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $43.87M | $54.35M | $50.32M | $50.67M | $56.25M |
| Cost of revenue | $43.07M | $48.79M | $46.43M | $46.61M | $49.69M |
| Gross profit | $800,000 | $5.56M | $3.88M | $4.06M | $6.55M |
| SG&A expense | $3.50M | $3.54M | $3.63M | $3.94M | $3.81M |
| Operating income | -$2.71M | $2.02M | $251,000 | $120,000 | $2.75M |
| Interest expense | $12,000 | $46,000 | $52,000 | $52,000 | $128,000 |
| Pretax income | -$2.56M | $2.06M | $268,000 | $100,000 | $2.60M |
| Income tax | $279,000 | $1.25M | $156,000 | $134,000 | -$1.24M |
| Net income | -$2.84M | $808,000 | $112,000 | -$34,000 | $3.84M |
| EBITDA | -$2.41M | $2.34M | $558,000 | $471,000 | $3.08M |
| EPS (basic) | -0.09 | 0.03 | 0.00 | 0.00 | 0.13 |
| EPS (diluted) | -0.09 | 0.03 | 0.00 | 0.00 | 0.12 |
| Weighted avg. shares (diluted) | 31.06M | 31.17M | 30.87M | 29.95M | 32.32M |
| Balance sheet | |||||
| Cash & equivalents | $4.47M | $3.62M | $1.68M | $1.32M | $331,000 |
| Receivables | $3.33M | $5.43M | $4.67M | $4.51M | $4.89M |
| Inventory | $9.14M | $9.36M | $11.24M | $10.26M | $11.05M |
| Current assets | $17.38M | $18.76M | $17.88M | $16.37M | $16.63M |
| PP&E, net | $1.75M | $1.72M | $1.80M | $1.65M | $1.91M |
| Total assets | $25.34M | $24.90M | $26.21M | $26.21M | $25.25M |
| Current liabilities | $5.80M | $4.25M | $6.12M | $4.83M | $5.26M |
| Short-term debt | — | — | — | $42,000 | $32,000 |
| Long-term debt | — | — | — | $7,000 | $53,000 |
| Total debt | — | — | — | $49,000 | $85,000 |
| Total liabilities | $7.67M | $4.58M | $6.97M | $6.57M | $6.67M |
| Shareholders' equity | $17.67M | $20.32M | $19.24M | $18.86M | $18.57M |
| Net debt | — | — | — | -$1.27M | -$246,000 |
| Shares outstanding | 31.06M | 31.06M | 30.10M | 29.95M | 29.95M |
| Cash flow statement | |||||
| Operating cash flow | $1.24M | $2.06M | $943,000 | $1.23M | $4.09M |
| Capital expenditure | $346,000 | $191,000 | $553,000 | $116,000 | $486,000 |
| Free cash flow | $895,000 | $1.87M | $390,000 | $1.12M | $3.60M |
| Investing cash flow | -$340,000 | -$205,000 | -$553,000 | -$111,000 | -$465,000 |
| Financing cash flow | -$45,000 | $78,000 | -$29,000 | -$136,000 | -$3.50M |
| Depreciation & amortization | $293,000 | $318,000 | $307,000 | $351,000 | $336,000 |
| Stock-based compensation | $192,000 | $185,000 | $252,000 | $320,000 | $369,000 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.